BioNTech SE (NASDAQ:BNTX) Shares Sold by First Trust Advisors LP

First Trust Advisors LP lowered its position in BioNTech SE (NASDAQ:BNTXFree Report) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 416,891 shares of the company’s stock after selling 2,419 shares during the quarter. First Trust Advisors LP owned approximately 0.18% of BioNTech worth $43,999,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BNTX. Vanguard Personalized Indexing Management LLC purchased a new stake in BioNTech in the third quarter valued at approximately $445,000. Pathstone Family Office LLC purchased a new stake in BioNTech in the third quarter valued at approximately $217,000. Campbell & CO Investment Adviser LLC lifted its stake in BioNTech by 17.8% in the third quarter. Campbell & CO Investment Adviser LLC now owns 2,673 shares of the company’s stock valued at $290,000 after buying an additional 404 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its stake in BioNTech by 13.2% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 241,580 shares of the company’s stock valued at $26,245,000 after buying an additional 28,230 shares during the last quarter. Finally, Midwest Professional Planners LTD. raised its stake in shares of BioNTech by 8.5% during the third quarter. Midwest Professional Planners LTD. now owns 2,822 shares of the company’s stock worth $307,000 after purchasing an additional 220 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Down 1.4 %

BioNTech stock opened at $100.34 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. The firm has a market capitalization of $23.85 billion, a price-to-earnings ratio of 200.68 and a beta of 0.27. BioNTech SE has a fifty-two week low of $85.21 and a fifty-two week high of $125.83. The stock’s fifty day moving average is $92.27 and its two-hundred day moving average is $95.84.

BioNTech (NASDAQ:BNTXGet Free Report) last posted its earnings results on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The firm had revenue of $203.69 million during the quarter, compared to analyst estimates of $589.96 million. BioNTech had a net margin of 4.01% and a return on equity of 0.55%. Analysts predict that BioNTech SE will post -2.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on BNTX. The Goldman Sachs Group cut their price target on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 28th. HC Wainwright restated a “buy” rating and set a $113.00 price target on shares of BioNTech in a research note on Thursday, May 30th. BMO Capital Markets cut their price target on BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research note on Tuesday, May 7th. UBS Group cut their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $171.00 price target on shares of BioNTech in a research note on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, BioNTech has an average rating of “Hold” and an average target price of $111.70.

Read Our Latest Analysis on BioNTech

About BioNTech

(Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Recommended Stories

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.